Marcus Schindler (L) and Paul Biondi (Novo Nordisk, Flagship Pioneering)

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at dis­cov­er­ing new drugs

No­vo Nordisk es­tab­lished its R&D rep around its in-house ex­per­tise that ul­ti­mate­ly birthed the GLP-1 block­buster semaglu­tide and pushed it to ma­jor-mar­ket fran­chise sta­tus. But its top ex­ecs have been crys­tal clear that the path to the fu­ture of R&D — mov­ing past semaglu­tide on to the next big thing — points to more ex­ter­nal al­liances, mar­ry­ing its glob­al re­search arms in and out of Copen­hagen with out­side groups spark­ing head­lines around their dis­cov­ery work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.